New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Iggo, Richard D ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; STEROID RECEPTOR; WNT PROTEIN;

ACCURACY; APOCRINE CARCINOMA; APOCRINE GLAND; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; MAMMARY GLAND; SIGNAL TRANSDUCTION; FEMALE; GENETICS; LETTER; METABOLISM; PATHOLOGY;

APOCRINE GLANDS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 83755169121     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3036     Document Type: Article

References (10)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928.
3. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
4. Oftedal OT. The mammary gland and its origin during synapsid evolution. J Mammary Gland Biol Neoplasia 2002, 7:225-252. 10.1023/A:1022896515287, 12751889.
5. Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010, 12:R63. 10.1186/bcr2626, 2949656, 20712882.
6. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Shirley Liu X, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011, 20:119-131. 10.1016/j.ccr.2011.05.026, 21741601.
7. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 2011, 30:3019-3027. 10.1038/emboj.2011.216, 21701558.
8. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008. 10.1038/sj.onc.1209415, 16491124.
9. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004, 6:517-527. 10.1016/j.ccr.2004.09.031, 15542435.
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, , et al. COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005. 10.1056/NEJMoa1014618, 21612468, COU-AA-301 Investigators.